Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 30/100

Failure Rate

12.8%

39 terminated/withdrawn out of 305 trials

Success Rate

86.2%

-0.3% vs industry average

Late-Stage Pipeline

52%

160 trials in Phase 3/4

Results Transparency

66%

161 of 243 completed trials have results

Key Signals

13 recruiting161 with results31 terminated8 withdrawn

Enrollment Performance

Analytics

Phase 3

140(47.1%)

Phase 1

75(25.3%)

Phase 2

59(19.9%)

Phase 4

20(6.7%)

N/A

3(1.0%)

297Total

Phase 3(140)

Phase 1(75)

Phase 2(59)

Phase 4(20)

+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (305)

Showing 20 of 305 trials

NCT07209761Phase 3Recruiting

A Study of Quabodepistat-containing Regimens for the Treatment of Drug-resistant Pulmonary Tuberculosis

Role: lead

NCT06973577Phase 3Completed

P3b Short-term Study of CTN in Patients With ADHD and Comorbid Anxiety

Role: lead

NCT05781399Phase 1Completed

First-in-Human, Multiple Part Clinical Study of JNT-517 in Healthy Participants and in Participants With Phenylketonuria

Role: lead

NCT07446400Phase 1Recruiting

A Trial to Examine the Interaction of Repinatrabit With Ethinyl Estradiol/Norethindrone, Metformin,Carbamazepine, Rosuvastatin, and Methotrexate When Administered Together

Role: lead

NCT05248659Phase 2Enrolling By Invitation

Trial of Sibeprenlimab in the Treatment of Immunoglobulin A Nephropathy (IgAN)

Role: lead

NCT07314333Phase 1Completed

A Trial to Assess How Centanafadine Interacts With Stimulants in the Body

Role: lead

NCT06971731Phase 3Recruiting

A Study of JNT-517 in Participants With Phenylketonuria (PKU)

Role: lead

NCT03719443Phase 1Completed

First in Human Study to Assess Safety of VIS649 in Healthy Subjects

Role: lead

NCT05007821Phase 2Completed

Linezolid Dosing Strategies in Drug-Resistant TB

Role: collaborator

NCT06628128Phase 3Recruiting

A Long-Term Study of JNT-517 in Participants With Phenylketonuria

Role: lead

NCT01939353Phase 2Completed

Study of Flexible Doses of the Triple Reuptake Inhibitor EB-1020 Sustained Release (SR) in the Treatment of Adult Males With Attention-Deficit Hyperactivity Disorder

Role: lead

NCT02402595Phase 1Completed

Drug Interaction Study Between AVP-923 and Itraconazole and Between AVP-786 and Itraconazole in Healthy Adult Subejcts

Role: lead

NCT02411695Phase 1Completed

Study to Assess the Safety, Tolerability and Pharmacokinetics of Oral Brexpiprazole (OPC- 34712) in Adolescents With Schizophrenia

Role: lead

NCT01430494Completed

Observational Study in Patients With Autosomal Dominant Polycystic Kidney Disease

Role: lead

NCT01787747Phase 1Completed

Pharmacokinetics (PK) and Tolerability of AVP-786 in Healthy Volunteers